

DAFTAR PUSTAKA

1. Rapuano CJ, Moster SJ. Glaucoma. In: Tanna AP, Boland MV, Giaconi JA, editors. *Basic and Clinical Science Course Section 10*. San Francisco: American Academy of Ophthalmology; 2023. p. 3–111.
2. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;5(12):e1221–34.
3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081–90.
4. Kementerian Kesehatan RI. *Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Glaukoma di Indonesia*. Jakarta: Kemenkes RI; 2019.
5. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. *Lancet*. 2017;390(10108):2183–93.
6. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 2007;35(4):495–516.
7. Parisi V, Oddone F, Ziccardi L, Roberti G, Coppola G, Manni G. Citicoline and retinal ganglion cells: effects on morphology and function. *Curr Neuropharmacol*. 2018;16(7):919–32.
8. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma preferred practice pattern®. *Ophthalmology*. 2021;128(1):P71–150.
9. Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. *Dtsch Arztebl Int*. 2020;117(13):225–34.
10. Maiciulaitiene R, Januleviciene I. Correlation between structure and function in glaucomatous damage. In: Grzybowski A, editor. *Biophysical Properties in Glaucoma*. Cham: Springer; 2019. p. 145–9.
11. Kanski JJ. *Clinical Ophthalmology: A Systematic Approach*. 9th ed. Philadelphia: Elsevier; 2020. p. 246–51.
12. Medeiros FA, Zangwill LM, Bowd C, Vessani RM, Susanna R Jr, Weinreb RN. Estimating the rate of retinal ganglion cell loss in glaucoma. *Am J Ophthalmol*. 2012;154(5):814–24.e1.
13. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA*. 2014;311(18):1901–11.
14. Boland MV, Tanna AP, Giaconi JA, et al. *Basic and Clinical Science Course Section 10*. San Francisco: American Academy of Ophthalmology; 2023.
15. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. *Prog Retin Eye Res*. 2006;25(5):490–513.
16. Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. *Exp Eye Res*. 2010;91(1):48–53.
17. Ferreira SM, Reides CG, Lerner FS, Llesuy SF. Evidence of oxidative stress damage in glaucoma. In: Kubena T, editor. *The Mystery of Glaucoma*. Rijeka: InTechOpen; 2011. p. 3–20.
18. Tanito M, Kaidzu S, Takai Y, Ohira A. Status of systemic oxidative stress in patients with primary open-angle glaucoma and pseudoexfoliation syndrome. *PLoS One*. 2012;7(11):e49680.
19. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr*. 2003;22(1):18–35.

20. Mou Z, et al. Vitamin C reduces the loss of retinal ganglion cells in chronic glaucoma by inhibiting neuroinflammation. *Nutr Neurosci*. 2025;;1–19. doi:10.1080/1028415X.2025.2509337.
21. Li S, Jakobs TC. Vitamin C protects retinal ganglion cells via SPP1 in glaucoma and after optic nerve damage. *Life Sci Alliance*. 2023;6(8):e202301976.
22. Duarte TL, Lunec J. When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. *Free Radic Res*. 2005;39(7):671–86.
23. Mandl J, Szarka A, Bánhegyi G. Vitamin C: update on physiology and pharmacology. *Br J Pharmacol*. 2009;157(7):1097–110.
24. Mwanza JC, Durbin M, Budenz DL, Girkin CA, Leung CK, Liebmann JM, et al. Profile and predictors of normal ganglion cell–inner plexiform layer thickness measured with frequency-domain optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2011;52(11):7872–9.
25. Thomas CN, Berry M, Logan A, Blanch RJ, Ahmed Z. Caspases in retinal ganglion cell death and axon regeneration. *Cell Death Discov*. 2017;3:17032.
26. Wang SY, Singh K, Lin SC. Glaucoma and vitamins A, C, and E supplement intake and serum levels in a population-based sample of the United States. *Eye (Lond)*. 2013;27(4):487–94.
27. Levin LA. Glaucoma. In: Tasman W, Jaeger EA, editors. *Duane's Ophthalmology*. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1341–5.
28. Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. *Am J Ophthalmol*. 2006;141(1):24–30.
29. Cantor LB, Rapuano CJ, Cioffi AM. Glaucomatous optic neuropathy. In: *Basic and Clinical Science Course, Section 10: Glaucoma*. San Francisco: American Academy of Ophthalmology; 2020. p. 3–16.
30. Levin LA. Glaucoma. In: Tasman W, Jaeger EA, editors. *Duane's Ophthalmology*. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1341–5.
31. Morgan J. Pathogenesis of glaucomatous optic neuropathy. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. *Glaucoma Medical Diagnosis & Therapy*. Amsterdam: Elsevier; 2009. p. 45–53.
32. Tanna AP, Boland MV, Giacony JA, Krishnan C, Lin SC, Medeiros FA, et al. Clinical evaluation and imaging of the posterior segment: optic nerve, retinal nerve fiber layer, and macula in glaucoma. In: *Basic and Clinical Science Course, Section 10: Glaucoma*. San Francisco: American Academy of Ophthalmology; 2021. p. 59.
33. Nakla M, Caprioli J, Morgan JA. Glaucomatous optic neuropathy. In: Grehn F, Stamper RL, editors. *Glaucoma: Science and Practice*. New York: Thieme; 2003. p. 94–102.
34. Morrison JC, Pollack IP. Determinants of intraocular pressure. In: Grehn F, Stamper RL, editors. *Glaucoma: Science and Practice*. New York: Thieme; 2003. p. 24–33.
35. John C. Morrison & Irvin P. Pollack. Determinants of Intraocular Pressure. in *Glaucoma : Science and Practice*, 2003.p 24–33
36. Luo X, Shen YM, Jiang MN, Lou XF, Shen Y. Ocular blood flow autoregulation mechanisms and methods. *J Ophthalmol*. 2015;2015:864871.
37. Weinreb NH. Anatomy, physiology, and pathophysiology. In: Ritch R, Shields MB, Krupin T, editors. *The Glaucoma: Basic and Clinical Science Handbook*. New York: Taylor & Francis e-Library; 2003. p. 11–7.
38. Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying ‘target’ intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. *Indian J Ophthalmol*. 2018;66(4):495–505.

39. Susanna R, Vessani RM. Staging glaucoma patient: why and how? *Open Ophthalmol J.* 2009;3:59–64.
40. Agarwal A, Kumar DA. History, principles, and instrumentation of optical coherence tomography. In: *Essentials of OCT in Ocular Disease*. New York: Thieme Medical Publishers; 2016. p. 2–8.
41. Cantor LB, Levin LA, Rapuano CJ, editors. The eye. In: *Basic and Clinical Science Course, Section 2: Fundamentals and Principles of Ophthalmology*. San Francisco: American Academy of Ophthalmology; 2021. p. 3–16.
42. Ross MH, Pawlina W. *Histology: A Text and Atlas*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
43. Stamper RL, Lieberman MF, Drake MV. *Diagnosis and Therapy of the Glaucoma*. 8th ed. St. Louis: Mosby Elsevier; 2009. p. 153–60.
44. Kaufman PL, Alm A. Retina section. In: Levin LA, Nilsson SFE, Ver Hoeve J, Wu SM, editors. *Adler's Physiology of the Eye: Retina*. St. Louis: Mosby; 2002. p. 371–80.
45. Sinai MJ. Direct ganglion cell assessment with the RTVue: the ganglion cell complex analysis. 2015. P 15-29.
46. Morgan JE. Retinal ganglion cell degeneration in glaucoma: an opportunity missed? *Clin Exp Ophthalmol.* 2012;40(4):364–8.
47. Carl Zeiss Meditec Inc. *CIRRUS HD-OCT from ZEISS: How to Read the Reports*. California: Carl Zeiss Meditec; 2011.
48. Esporcatte BL, Kara-José AC, Melo LA, Pinto LM, Tavares IM. The estimates of retinal ganglion cell counts performed better than isolated structure and functional tests for glaucoma diagnosis. *J Ophthalmol.* 2017;2017:1–6.
49. Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. *Exp Eye Res.* 2011;93(3):265–70.
50. Feng KM, Tsung TH, Chen YH, Lu DW. The role of retinal ganglion cell structure and function in glaucoma. *Cells.* 2023;12(24):2797.
51. Micelli-Ferrari T, Vendemiale G, Grattagliano I, Altomare E, Cardia L, Tata AM, et al. Role of lipid peroxidation in the pathogenesis of retinal diseases. *Eur J Ophthalmol.* 1996;6(1):1–7.
52. Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. *Free Radic Biol Med.* 2009;46(6):719–30.
53. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. *Biochim Biophys Acta.* 2012;1826(2):443–57.
54. Zhang ZQ, Xie Z, Chen SY, Zhang XM. Mitochondrial dysfunction in glaucomatous degeneration. *Int J Ophthalmol.* 2023;16(5):811–823. doi:10.18240/ijo.2023.05.20
55. Pease ME, Zack DJ, Berlinicke C, Mandell LM, Cone FE, Quigley HA. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. *Invest Ophthalmol Vis Sci.* 2009;50(5):2194–2200.
56. Kong GYX, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. *J Glaucoma.* 2009;18(2):93–100.
57. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. *Invest Ophthalmol Vis Sci.* 1995;36(5):774–786.
58. Gracia Pharmindo. Vitalong C® 500 mg Extended-Release Tablet [product insert]. Jakarta, Indonesia: PT Gracia Pharmindo; 2020.
59. Padayatty SJ, Levine M. New insights into the physiology and pharmacology of vitamin C. *CMAJ.* 2001;164(3):353–355.
60. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication

- delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120(6):701–713.
61. Doozandeh A, Yazdani S. Neuroprotection in glaucoma. *J Ophthalmic Vis Res.* 2016;11(2):209–220. doi:10.4103/2008-322X.183923
 62. Leung CKS, Cheung CYL, Weinreb RN, Qiu Q, Liu S, Li H, et al. Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. *Invest Ophthalmol Vis Sci.* 2010;51(1):217–222.
 63. Gallo Afflitto, G., Aiello, F., Cesareo, M. & Nucci, C. Primary Open Angle Glaucoma Prevalence in Europe: A Systematic Review and Meta-Analysis. *Journal of Glaucoma* vol. 31 783–788 (2022).
 64. Banik, S., Ghosh, A. & Debi, H. The Prevalence Trend of Glaucoma by Age and Sex Difference in South Asia: A Systematic Review and Meta-Analysis of Population-Based Studies. *Health Sci. Rep.* **8**, (2025).
 65. Sekimitsu, S. *et al.* Deep Ocular Phenotyping Across Primary Open-Angle Glaucoma Genetic Burden. in *JAMA Ophthalmology* vol. 141 891–899 (American Medical Association, 2023).
 66. Kim, Y. K., Choi, H. J., Jeoung, J. W., Park, K. H. & Kim, D. M. Five-year incidence of primary open-angle glaucoma and rate of progression in health center-based Korean population: The Gangnam eye study. *PLoS One* **9**, (2014).
 67. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. *Ophthalmology.* 2021;128(1):P71–150.
 68. Yamamoto, S. *et al.* Primary open-angle glaucoma in a population associated with high prevalence of primary angle-closure glaucoma: The kumejima study. *Ophthalmology* **121**, 1558–1565 (2014).
 69. Ekström, C. & Carlsson, C. Incidence of blindness in open-angle glaucoma in Sweden: a long-term follow-up study. *Ups. J. Med. Sci.* **129**, (2024).
 70. Liang, Y. B. *et al.* Prevalence of primary open angle glaucoma in a rural adult chinese population: The Handan eye study. *Invest. Ophthalmol. Vis. Sci.* **52**, 8250–8257 (2011).
 71. Shin, J. W., Sung, K. R., Lee, G. C., Durbin, M. K. & Cheng, D. Ganglion Cell–Inner Plexiform Layer Change Detected by Optical Coherence Tomography Indicates Progression in Advanced Glaucoma. *Ophthalmology* **124**, 1466–1474 (2017).
 72. Hu, H. *et al.* Associations of Ganglion Cell–Inner Plexiform Layer and Optic Nerve Head Parameters with Visual Field Sensitivity in Advanced Glaucoma. *Ophthalmic Res.* **64**, 310–320 (2021).
 73. Shin, J. W., Sung, K. R. & Park, S. W. Patterns of Progressive Ganglion Cell–Inner Plexiform Layer Thinning in Glaucoma Detected by OCT. *Ophthalmology* **125**, 1515–1525 (2018).
 74. Hou, H. *et al.* Ganglion Cell Complex Thickness and Macular Vessel Density Loss in Primary Open-Angle Glaucoma. in *Ophthalmology* vol. 127 1043–1052 (Elsevier Inc., 2020).
 75. Kaczmarek, I. A., Prost, M. E. & Różycki, R. Evaluation of Ganglion Cell–Inner Plexiform Layer Thickness in the Diagnosis of Preperimetric and Early Perimetric Glaucoma. *J. Clin. Med.* **14**, (2025).
 76. Pham, J. H. & Stankowska, D. L. Mitochondria-associated endoplasmic reticulum membranes (MAMs) and their role in glaucomatous retinal ganglion cell degeneration—a mini review. *Frontiers in Neuroscience* vol. 17 (2023).
 77. Lee, H. J., Kim, M. S., Jo, Y. J. & Kim, J. Y. Ganglion Cell–Inner Plexiform Layer Thickness in Retinal Diseases: Repeatability Study of Spectral-Domain Optical Coherence Tomography. *Am. J. Ophthalmol.* **160**, 283–289.e1 (2015).

78. Leys, C., Ley, C., Klein, O., Bernard, P. & Licata, L. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. *J. Exp. Soc. Psychol.* 49, 764–766 (2013).
79. Sato, A., Kondo, Y. & Ishigami, A. The evidence to date: implications of l-ascorbic acid in the pathophysiology of aging. *Journal of Physiological Sciences* vol. 74 Preprint at <https://doi.org/10.1186/s12576-024-00922-7> (2024).
80. Carr, A. C. & Zawari, M. Does Aging Have an Impact on Vitamin C Status and Requirements? A Scoping Review of Comparative Studies of Aging and Institutionalisation. *Nutrients* vol. 15 Preprint at <https://doi.org/10.3390/nu15040915> (2023).
81. Monacelli, F., Acquarone, E., Giannotti, C., Borghi, R. & Nencioni, A. Vitamin C, aging and Alzheimer's disease. *Nutrients* vol. 9 Preprint at <https://doi.org/10.3390/nu9070670> (2017).
82. Cui, N., Jia, J. & He, Y. Glaucomatous retinal ganglion cells: death and protection. *International Journal of Ophthalmology* vol. 18 160–167 Preprint at <https://doi.org/10.18240/ijo.2025.01.20> (2025).
83. Xu, Y. *et al.* Oxidative stress in glaucomatous retinal ganglion cell injury: Mechanisms and neuroprotective strategies. *Exp. Eye Res.* 264, 110837 (2026).
84. Catalani, E., Brunetti, K., Del Quondam, S. & Cervia, D. Targeting Mitochondrial Dysfunction and Oxidative Stress to Prevent the Neurodegeneration of Retinal Ganglion Cells. *Antioxidants* vol. 12 (2023).
85. Garcia-Medina, J. J. *et al.* A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: An open-label, randomized, controlled trial. in *Acta Ophthalmologica* vol. 93 546–554 (Blackwell Publishing Ltd, 2015).
86. Bao, J. *et al.* Effect of antioxidants on primary open-angle glaucoma: a systematic review and meta-analysis. *Frontiers in Pharmacology* vol. 16 (2025).
87. Giunta, P. *et al.* Impact of Oral Citicoline, Antioxidant Vitamins, and Blackcurrant Supplementation on Primary Open-Angle Glaucoma: An OCT and OCTA Study. *Biomedicines* 13, (2025).

